Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNTX-101
- Development stage
- Preclinical
- Lead developer
- January Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
JNTX-101 is a novel albumin-encapsulated gemcitabine prodrug developed by January Therapeutics. It is designed to improve the therapeutic index of gemcitabine, a standard-of-care chemotherapy for various solid tumors, by utilizing human serum albumin (HSA) as a nanoparticle carrier. The drug's uptake and efficacy are significantly influenced by the expression of Caveolin-1 (Cav-1), which facilitates the internalization of albumin-bound drugs into cancer cells. Preclinical studies in pancreatic and lung cancer models suggest that Cav-1 may serve as a potential predictive biomarker for JNTX-101 sensitivity, particularly in nutrient-deprived conditions where albumin uptake is often upregulated by tumor cells.
- Other names
- albumin encapsulated gemcitabine prodrug
02
Targets
RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on JNTX-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNTX-101.